Advertisement
Screener

VIATRIS INC. (VTRS) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

VIATRIS INC. Operating Cash Flow

VIATRIS INC. (VTRS) reported Operating Cash Flow of $770.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • VIATRIS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $381.80M, a 73.78% increase year-over-year.
  • VIATRIS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $388.30M, a 27.49% decline year-over-year.
  • VIATRIS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $815.80M, a 69.01% increase year-over-year.
  • VIATRIS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $744.90M, a 9.87% decline year-over-year.
  • VIATRIS INC. net cash provided by (used in) operating activities for fiscal 2025 was $2.32B, a 0.56% increase from fiscal 2024.
  • VIATRIS INC. net cash provided by (used in) operating activities for fiscal 2024 was $2.30B, a 20.59% decline from fiscal 2023.
  • VIATRIS INC. net cash provided by (used in) operating activities for fiscal 2023 was $2.90B, a 3.30% decline from fiscal 2022.
  • VIATRIS INC. net cash provided by (used in) operating activities for fiscal 2022 was $3.00B, a 0.59% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Operating Activities 1 monthNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 4 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 7 monthNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 11 monthNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30$381.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$770.10M
10-Q · filed 2026-08-06
$1.59B
derived: sum of 3 quarters · filed 2026-08-06
$2.33B
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$388.30M
10-Q · filed 2026-05-07
$1.20B
derived: sum of 2 quarters · filed 2026-05-07
$1.95B
derived: sum of 3 quarters · filed 2026-05-07
$2.17B
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$815.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$1.56B
derived: sum of 2 quarters · filed 2026-02-26
$1.78B
derived: sum of 3 quarters · filed 2026-08-06
$2.32B
10-K · filed 2026-02-26
2025-09-30$744.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$964.60M
derived: sum of 2 quarters · filed 2026-08-06
$1.50B
10-Q · filed 2025-11-06
$1.98B
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$219.70M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$755.20M
10-Q · filed 2026-08-06
$1.24B
derived: sum of 3 quarters · filed 2026-08-06
$2.06B
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$535.50M
10-Q · filed 2026-05-07
$1.02B
derived: sum of 2 quarters · filed 2026-05-07
$1.84B
derived: sum of 3 quarters · filed 2026-05-07
$2.22B
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$482.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$1.31B
derived: sum of 2 quarters · filed 2026-02-26
$1.69B
derived: sum of 3 quarters · filed 2026-02-26
$2.30B
10-K · filed 2026-02-26
2024-09-30$826.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$1.21B
derived: sum of 2 quarters · filed 2025-11-06
$1.82B
10-Q · filed 2025-11-06
$2.39B
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$379.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$993.70M
10-Q · filed 2025-08-07
$1.56B
derived: sum of 3 quarters · filed 2026-02-26
$2.40B
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$614.60M
10-Q · filed 2025-05-08
$1.18B
derived: sum of 2 quarters · filed 2026-02-26
$2.02B
derived: sum of 3 quarters · filed 2026-02-26
$2.54B
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$568.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$1.40B
derived: sum of 2 quarters · filed 2026-02-26
$1.93B
derived: sum of 3 quarters · filed 2026-02-26
$2.90B
10-K · filed 2026-02-26
$2.80B
10-K · filed 2024-02-28
2023-09-30$835.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$1.36B
derived: sum of 2 quarters · filed 2024-11-07
$2.33B
10-Q · filed 2024-11-07
$2.32B
10-Q · filed 2023-11-08
$2.52B
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$525.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$1.50B
10-Q · filed 2024-08-08
$1.49B
10-Q · filed 2023-08-07
$1.69B
derived: sum of 3 quarters · filed 2025-02-27
$2.55B
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$971.20M
10-Q · filed 2024-05-09
$1.16B
derived: sum of 2 quarters · filed 2025-02-27
$2.03B
derived: sum of 3 quarters · filed 2025-02-27
$2.83B
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31$189.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$1.06B
derived: sum of 2 quarters · filed 2025-02-27
$1.86B
derived: sum of 3 quarters · filed 2025-02-27
$3.00B
10-K · filed 2025-02-27
$2.95B
10-K · filed 2023-02-27
2022-09-30$869.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$1.67B
derived: sum of 2 quarters · filed 2023-11-08
$2.81B
10-Q · filed 2023-11-08
$3.33B
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$802.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$1.94B
10-Q · filed 2023-08-07
$2.46B
derived: sum of 3 quarters · filed 2024-02-28
$3.55B
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31$1.14B
10-Q · filed 2023-05-08
$1.66B
derived: sum of 2 quarters · filed 2024-02-28
$2.75B
derived: sum of 3 quarters · filed 2024-02-28
$3.31B
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31$523.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$1.61B
derived: sum of 2 quarters · filed 2024-02-28
$2.17B
derived: sum of 3 quarters · filed 2024-02-28
$3.02B
10-K · filed 2024-02-28
2021-09-30$1.09B
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$1.65B
derived: sum of 2 quarters · filed 2022-11-07
$2.49B
10-Q · filed 2022-11-07
$2.53B
derived: sum of 4 quarters · filed 2023-02-27
2021-06-30$559.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08
$1.41B
10-Q · filed 2022-08-08
$1.44B
derived: sum of 3 quarters · filed 2023-02-27
$1.97B
derived: sum of 4 quarters · filed 2023-02-27
2021-03-31$848.80M
10-Q · filed 2022-05-09
$885.00M
derived: sum of 2 quarters · filed 2023-02-27
$1.41B
derived: sum of 3 quarters · filed 2023-02-27
2020-12-31$36.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27
$561.20M
derived: sum of 2 quarters · filed 2023-02-27
$1.23B
10-K · filed 2023-02-27
2020-09-30$525.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
$1.20B
10-Q · filed 2021-11-08
2020-09-27-$669.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10
-$290.10M
derived: sum of 2 quarters · filed 2021-08-09
$1.00M
10-Q · filed 2020-11-10
2020-06-30$379.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
$670.60M
10-Q · filed 2021-08-09
2020-06-28-$291.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12
$0.00
10-Q · filed 2020-08-12
2020-03-31$291.10M
10-Q · filed 2021-05-10
2020-03-29$0.00
10-Q · filed 2020-05-12
2019-12-31$0.00
10-K · filed 2020-05-07
$1.80B
10-K · filed 2022-02-28
2019-09-29$0.00
10-Q · filed 2020-11-10
2019-06-30$0.00
10-Q · filed 2020-08-12
2019-03-31$0.00
10-Q · filed 2020-05-12
2018-12-31$2.34B
10-K · filed 2021-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Royalty Pharma plc (RPRX)United States$22.628B
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
INSMED Inc (INSM)United States$26.566B-26.60
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17